The Market for Antibacterials, Valued at $24 Billion in the Seven Major Markets, Faces Significant Revenue Loss in the Period 2005-2007 Due to Major Patent Expiries.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c27776) has announced the addition of Antibacterials - Pharma Strikes Antibac to their offering Rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid), has been driven by the increasing numbers of immunocompromised immunocompromised /im·mu·no·com·pro·mised/ (-kom´pro-mizd) having the immune response attenuated by administration of immunosuppressive drugs, by irradiation, by malnutrition, or by certain disease processes (e.g., cancer). patients in hospitals. Despite these pockets of strong growth, the market for antibacterials, valued at $24 billion in the seven major markets, still faces significant revenue loss in the period 2005-2007 due to major patent expiries. This report highlights epidemiological trends in bacterial infections across the major Western markets. It provides an in-depth value analysis per product, class and country, with an assessment of underlying commercial and clinical influencers. A case study analysis of Pfizer's Zmax single dose formulation for respiratory tract infections is provided, including the impact of generic azithromycin. The report examines the outlook for branded Rocephin in the key US market discussion of Sandoz, Lupin, and Hospira strategies for generic ceftriaxone ceftriaxone /cef·tri·ax·one/ (cef?tri-ak´son) a semisynthetic, ß–resistant, third-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria, used as the sodium salt. . In 2004 the global antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. market was valued at approximately $24 billion with modest growth on 2000 (CAGR CAGR See: Compound Annual Growth Rate 4.4%). The fastest growing classes during this period were the carbapenems and "others" with notable products such as Pfizers Zyvox (linezolid). Although drug resistant infections such as MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. have been a key focus over recent years, This opinion leader research reveals new concerns with Gram negative organisms such as actineobacter, pseudomonas Pseudomonas A genus of gram-negative, nonsporeforming, rod-shaped bacteria. Motile species possess polar flagella. They are strictly aerobic, but some members do respire anaerobically in the presence of nitrate. and ESBL ESBL Extended Spectrum Beta Lactamase ESBL East Staffordshire Badminton League (UK) producing strains. Pfizer's acquisition of Vircurons dalbavancin and Johnsons and Johnson's investment in both doripenem and ceftobipole brings much need reinvestment to the antibacterial sector and a commitment to combating serious hospital infections. Reasons to Purchase - Review the clinical and commercial factors driving new product decisions in antibacterials, and the opportunities and threats facing the market - Gain insight into the product lifecycle Product lifecycle or product life cycle is the course of a product's sales and profits over time. The five stages of each product lifecycle are product development, introduction, growth, maturity and decline. management strategies of the top antibacterial players through real case study analyses - Understand why 2005 has brought new investment to a previously neglected therapeutic sector Case Studies: - Pfizer - GlaxoSmithKline - Johnson & Johnson - Abbott - Roche For more information visit http://www.researchandmarkets.com/reports/c27776 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion